YU20999A - Heterociklični derivati koji inhibiraju faktor xa - Google Patents

Heterociklični derivati koji inhibiraju faktor xa

Info

Publication number
YU20999A
YU20999A YU20999A YU20999A YU20999A YU 20999 A YU20999 A YU 20999A YU 20999 A YU20999 A YU 20999A YU 20999 A YU20999 A YU 20999A YU 20999 A YU20999 A YU 20999A
Authority
YU
Yugoslavia
Prior art keywords
faktor
inhibit
heterocycle derivatives
relates
antithrombotic
Prior art date
Application number
YU20999A
Other languages
English (en)
Inventor
John Preston
Andrew Stocker
Paul Turner
Michael James Smithers
John Wall Rayner
Original Assignee
Sygenta Limited Sygenta European Regional Centre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9623283.0A external-priority patent/GB9623283D0/en
Priority claimed from GBGB9715893.5A external-priority patent/GB9715893D0/en
Application filed by Sygenta Limited Sygenta European Regional Centre filed Critical Sygenta Limited Sygenta European Regional Centre
Publication of YU20999A publication Critical patent/YU20999A/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56Amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Pronalazak se odnosi na heterociklične derivate sa formulom (I): A-B-X1-T1(R2)-L1-T2(R3)-X2-Q ili njihove farmaceutski prihvatljive soli, koje poseduju antitrombotička i antikoagulantska svojstva usled njihove inhibicije faktora Xa i koji su prema tome korisna u postupcima za lečenje ljudi i životinja. Pronalazak se isto odnosi na procese za dobijanje hetorocikličnih derivata, na farmaceutske kompozicije koje ih sadrže i na njihovu upotrebu u proizvodnji antitrobotičkog i antikoagulantskog efekta.[The invention relates to heterocyclic derivatives of the formula (I): A-B-X1-T1(R2)-L1-T2(R3)-X2-Q or pharmaceutically acceptable salts thereof, which possess antithrombotic and anticoagulant properties due to their inhibition of Factor Xa and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect.
YU20999A 1996-11-08 1997-11-04 Heterociklični derivati koji inhibiraju faktor xa YU20999A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9623283.0A GB9623283D0 (en) 1996-11-08 1996-11-08 Heterocyclic derivatives
GBGB9715893.5A GB9715893D0 (en) 1997-07-29 1997-07-29 Heterocyclic derivatives

Publications (1)

Publication Number Publication Date
YU20999A true YU20999A (sh) 2002-03-18

Family

ID=26310361

Family Applications (1)

Application Number Title Priority Date Filing Date
YU20999A YU20999A (sh) 1996-11-08 1997-11-04 Heterociklični derivati koji inhibiraju faktor xa

Country Status (28)

Country Link
US (2) US6300330B1 (sh)
EP (2) EP1358909A1 (sh)
JP (1) JP2001504113A (sh)
KR (1) KR20000053128A (sh)
CN (1) CN1220682C (sh)
AT (1) ATE258167T1 (sh)
AU (1) AU731929B2 (sh)
BG (1) BG64258B1 (sh)
BR (1) BR9712672A (sh)
CA (1) CA2266890A1 (sh)
CZ (1) CZ296342B6 (sh)
DE (1) DE69727308T2 (sh)
DK (1) DK0937048T3 (sh)
ES (1) ES2213208T3 (sh)
HU (1) HUP0001098A3 (sh)
IL (1) IL129706A (sh)
MY (1) MY124122A (sh)
NO (1) NO312894B1 (sh)
NZ (1) NZ334710A (sh)
PL (1) PL189703B1 (sh)
PT (1) PT937048E (sh)
RU (2) RU2213732C2 (sh)
SK (1) SK284665B6 (sh)
TR (1) TR199901006T2 (sh)
TW (1) TW458968B (sh)
UA (1) UA56197C2 (sh)
WO (1) WO1998021188A1 (sh)
YU (1) YU20999A (sh)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
JP2000504336A (ja) 1996-02-02 2000-04-11 ゼネカ・リミテッド 薬学製剤として有用なヘテロ環式化合物
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
US6440972B1 (en) 1997-02-13 2002-08-27 Zeneca Limited Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
DE69815509T2 (de) 1997-02-13 2004-05-13 Astrazeneca Ab Heterozyklische verbindungen die als oxido-squalen-zyklase-inhibitoren anwendung finden
DE69835430T2 (de) 1997-05-30 2007-03-08 Takeda Pharmaceutical Co. Ltd. Sulfonamidderivate, ihre herstellung und verwendung
GB9715894D0 (en) * 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
GB9715895D0 (en) * 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
DE69833036T2 (de) 1997-09-30 2006-06-22 Daiichi Pharmaceutical Co., Ltd. Sulfonylderivate
IL137517A0 (en) * 1998-01-27 2001-07-24 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl factor xa inhibitors
CA2317017A1 (en) 1998-02-05 1999-08-12 Takeda Chemical Industries, Ltd. Sulfonamide derivatives, their production and use
GB9809349D0 (en) 1998-05-02 1998-07-01 Zeneca Ltd Heterocyclic derivatives
DE69921994T2 (de) * 1998-05-02 2005-12-01 Astrazeneca Ab Heterozyklische verbindungen mit faktor xa hemmender wirkung
GB9809350D0 (en) * 1998-05-02 1998-07-01 Zeneca Ltd Novel salt
CA2340100A1 (en) * 1998-08-11 2000-02-24 Daiichi Pharmaceutical Co., Ltd. Novel sulfonyl derivatives
AU3127900A (en) 1998-12-23 2000-07-31 Du Pont Pharmaceuticals Company Thrombin or factor xa inhibitors
GB9902989D0 (en) * 1999-02-11 1999-03-31 Zeneca Ltd Heterocyclic derivatives
TW200404789A (en) 1999-03-15 2004-04-01 Axys Pharm Inc Novel compounds and compositions as protease inhibitors
GB9914342D0 (en) * 1999-06-19 1999-08-18 Zeneca Ltd Compound
CA2383492A1 (en) 1999-06-22 2000-12-28 Takeda Chemical Industries, Ltd. Acylhydrazine derivatives, their production and use
GB9917344D0 (en) * 1999-07-24 1999-09-22 Zeneca Ltd Novel salt
DE60041584D1 (de) * 1999-07-28 2009-04-02 Aventis Pharma Inc Substituierte oxoazaheterozyclische verbindungen
TWI288745B (en) * 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
GB0012448D0 (en) * 2000-05-24 2000-07-12 Astrazeneca Ab New process
BR0107282A (pt) * 2000-09-29 2004-07-06 Cor Therapeutics Inc Composto, composição farmacêutica e métodos para prevenir ou tratar uma condição em um mamìfero e para inibir a coagulação de amostras biológicas
BR0115075A (pt) 2000-11-02 2003-07-29 Hoffmann La Roche Benzo'b!tiofenos e benzo'd!isotiazóis para baixamento de colesterol
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
MXPA03005601A (es) 2000-12-22 2004-12-02 Axys Pharm Inc Nuevos compuestos y composiciones como inhibidores de catepsina.
WO2003000657A1 (fr) * 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
WO2003024986A1 (en) 2001-09-17 2003-03-27 Ortho-Mcneil Pharmaceutical, Inc. 6-o-carbamate-11,12-lacto-ketolide antimicrobials
WO2003042197A1 (en) 2001-11-14 2003-05-22 Aventis Pharmaceuticals Inc. Oligopeptides and compositions containing them as cathepsin s inhibitors
BR0214748A (pt) 2001-12-05 2004-11-23 Ortho Mcneil Pharm Inc Derivados 6-oacil-cetolidas de eritromicina, úteis como antibacterianos
AU2003265398A1 (en) * 2002-08-09 2004-02-25 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.
TW200500366A (en) * 2002-12-25 2005-01-01 Daiichi Seiyaku Co Diamine derivatives
US7501538B2 (en) * 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
AU2006216566A1 (en) * 2005-02-24 2006-08-31 Janssen Pharmaceutica N.V. Novel pyridine derivatives as potassium ion channel openers
WO2007008145A1 (en) * 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
JP4987324B2 (ja) * 2006-03-03 2012-07-25 エヌ・イーケムキャット株式会社 炭素−炭素結合の生成方法
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
AU2020300002A1 (en) 2019-07-01 2022-02-24 Tonix Pharma Limited Anti-CD154 antibodies and uses thereof
CN116963750A (zh) 2021-01-06 2023-10-27 通尼克斯制药有限公司 用经修饰的抗-cd154抗体诱导免疫耐受的方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT340933B (de) 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
US4167567A (en) 1978-05-05 1979-09-11 The Upjohn Company Antihypertensive 4-aminoquinolines
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
SE8203887D0 (sv) 1982-06-23 1982-06-23 Kabivitrum Ab Nya trombininhiberande foreningar
DE3246932A1 (de) 1982-12-16 1984-06-20 Schering AG, 1000 Berlin und 4709 Bergkamen Substituierte 5h-pyrimido(5,4-b)indole
FR2557570B1 (fr) 1984-01-04 1986-04-18 Adir Nouveaux derives de la quinoleine, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4840963A (en) 1984-03-14 1989-06-20 Merck & Co., Inc. 2-Sulfamoyl-1H-indole derivatives for the treatment of elevated intraocular pressure
GB8601160D0 (en) 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
GB8603120D0 (en) 1986-02-07 1986-03-12 Pfizer Ltd Anti-dysrhythmia agents
GB8609630D0 (en) 1986-04-19 1986-05-21 Pfizer Ltd Anti-arrhythmia agents
GB8710494D0 (en) 1987-05-02 1987-06-03 Pfizer Ltd Antiarrhythmic agents
JPH0696575B2 (ja) 1987-09-17 1994-11-30 三菱化成株式会社 4−アミノピリジン誘導体及びその酸付加塩
US4871721A (en) 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
GB8817315D0 (en) 1988-07-20 1988-08-24 Pfizer Ltd Triazole antifungal agents
GB8819307D0 (en) 1988-08-13 1988-09-14 Pfizer Ltd Antiarrhythmic agents
DE3905364A1 (de) 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
IL94805A (en) * 1989-06-28 1994-04-12 Ciba Geigy Ag Certain translocated carboxylic acids (a) Arylsulfonamide - and pyridyl - or imidazolil (), process for their preparation and pharmaceutical preparations containing them
IE64358B1 (en) 1989-07-18 1995-07-26 Ici Plc Diaryl ether heterocycles
US5032604A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Class III antiarrhythmic agents
DE3943225A1 (de) 1989-12-23 1991-06-27 Schering Ag Neue ss-carboline, verfahren zu deren herstellung und deren verwendung in arzneimitteln
EP0511347A1 (de) 1990-11-15 1992-11-04 Pentapharm A.G. Meta-substituierte phenylalanin-derivate
DE4036552C1 (sh) 1990-11-16 1992-02-06 Boehringer Mannheim Gmbh, 6800 Mannheim, De
EP0495750A3 (en) 1991-01-14 1992-09-16 Ciba-Geigy Ag Heterocyclic hydroxylamine
IT1245712B (it) 1991-04-09 1994-10-14 Boehringer Mannheim Italia Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree
FR2676054B1 (fr) 1991-05-03 1993-09-03 Sanofi Elf Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH07502014A (ja) 1991-06-21 1995-03-02 ベーリンガー マンハイム イタリア エス.ピー.エイ. 気道に対して抗喘息性、抗炎症性活性を有する2−アミノ−4−アリール−チアゾール
AU2573592A (en) 1991-09-19 1993-04-27 Smithkline Beecham Corporation Pyridine compounds for treating leukotriene-related diseases
PH31294A (en) 1992-02-13 1998-07-06 Thomae Gmbh Dr K Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them.
HU211995B (en) 1992-06-30 1996-01-29 Gyogyszerkutato Intezet Process to prepare novel benzoyl amino acid derivs. and pharmaceutical compns. contg.them
US5371091A (en) 1992-08-31 1994-12-06 Bristol-Myers Squibb Company Heteroaromatic amine thrombin inhibitors
FR2697252B1 (fr) 1992-10-28 1994-12-09 Fournier Ind & Sante Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique.
DE4243858A1 (de) 1992-12-23 1994-06-30 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5332822A (en) 1992-12-24 1994-07-26 Bristol-Myers Squibb Company Heteroaromatic and thioheteroaromatic substituted sulfonamide thrombin inhibitors
US5364865A (en) 1992-12-30 1994-11-15 Sterling Winthrop Inc. Phenoxy- and phenoxyalkyl-piperidines as antiviral agents
DE4302485A1 (de) 1993-01-29 1994-08-04 Merck Patent Gmbh Piperazinderivate
HUT68042A (en) 1993-02-10 1995-03-22 Pentapharm Ag Piperazides of substituted phenylalanine derivates as thrombin inhibitors
TW257757B (sh) 1993-03-03 1995-09-21 Boehringer Mannheim Gmbh
DE4306506A1 (de) 1993-03-03 1994-09-08 Boehringer Mannheim Gmbh Neue 4-Alkylaminopyridine - Verfahren zu ihrer Herstellung sowie diese Verbindungen enthaltende Arzneimittel
DE4306873A1 (de) 1993-03-05 1994-09-08 Boehringer Mannheim Gmbh Neue 4-Aminopyridine-Verfahren zu ihrer Herstellung sowie diese Verbindungen enthaltende Arzneimittel
PL310889A1 (en) 1993-03-29 1996-01-08 Zeneca Ltd Heterocyclic derivatives as inhibitors of thrombocytes aggregation
NZ262942A (en) 1993-03-29 1997-07-27 Zeneca Ltd Pyridyl substituted piperazine and various other derivatives of azaheteroaryl substituted piperazines; pharmaceutical compositions
US5681954A (en) 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
AU3107795A (en) 1994-08-09 1996-03-07 Pentapharm Ag Inhibitors of the benzamidine type
IL115420A0 (en) * 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
WO1996019223A1 (en) 1994-12-22 1996-06-27 Smithkline Beecham Corporation Fibrinogen receptor antagonists
WO1996019475A1 (en) 1994-12-22 1996-06-27 Smithkline Beecham Corporation Fibrinogen receptor antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5856326A (en) 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
IT1282797B1 (it) 1995-04-21 1998-03-31 Colla Paolo Pirril-(indolil)-aril-sulfoni e relativo processo di produzione ed impiego nella terapia delle infezioni da virus dell'aids
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
GB9602166D0 (en) * 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
JP2000504336A (ja) 1996-02-02 2000-04-11 ゼネカ・リミテッド 薬学製剤として有用なヘテロ環式化合物
GB9602294D0 (en) 1996-02-05 1996-04-03 Zeneca Ltd Heterocyclic compounds
CA2244851A1 (en) 1996-02-22 1997-08-28 Petrus Fredericus Wilhelmus Stouten M-amidino phenyl analogs as factor xa inhibitors
KR20000029984A (ko) 1996-08-14 2000-05-25 사라 엔 람베쓰 치환된피리미딘유도체및이의약학적용도
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні

Also Published As

Publication number Publication date
ES2213208T3 (es) 2004-08-16
UA56197C2 (uk) 2003-05-15
ATE258167T1 (de) 2004-02-15
US6300330B1 (en) 2001-10-09
EP0937048A1 (en) 1999-08-25
DE69727308T2 (de) 2004-11-18
SK61399A3 (en) 2000-02-14
CA2266890A1 (en) 1998-05-22
HUP0001098A2 (hu) 2001-06-28
NO992230D0 (no) 1999-05-07
DK0937048T3 (da) 2004-04-19
JP2001504113A (ja) 2001-03-27
MY124122A (en) 2006-06-30
WO1998021188A1 (en) 1998-05-22
PL333241A1 (en) 1999-11-22
KR20000053128A (ko) 2000-08-25
IL129706A0 (en) 2000-02-29
CZ163499A3 (cs) 1999-08-11
AU4874897A (en) 1998-06-03
BR9712672A (pt) 1999-10-26
RU2003115094A (ru) 2004-12-10
TR199901006T2 (xx) 1999-08-23
NO992230L (no) 1999-05-07
SK284665B6 (sk) 2005-08-04
AU731929B2 (en) 2001-04-05
HUP0001098A3 (en) 2002-03-28
CN1235597A (zh) 1999-11-17
TW458968B (en) 2001-10-11
NO312894B1 (no) 2002-07-15
PT937048E (pt) 2004-05-31
RU2213732C2 (ru) 2003-10-10
EP1358909A1 (en) 2003-11-05
PL189703B1 (pl) 2005-09-30
DE69727308D1 (de) 2004-02-26
CN1220682C (zh) 2005-09-28
IL129706A (en) 2004-09-27
EP0937048B1 (en) 2004-01-21
BG64258B1 (bg) 2004-07-30
US20030195203A1 (en) 2003-10-16
NZ334710A (en) 2000-11-24
US6936610B2 (en) 2005-08-30
CZ296342B6 (cs) 2006-02-15
BG103430A (en) 2000-07-31

Similar Documents

Publication Publication Date Title
YU20999A (sh) Heterociklični derivati koji inhibiraju faktor xa
IL133516A0 (en) Heterocyclic derivatives which inhibit factor xa
PL343706A1 (en) Heterocyclic derivatives which inhibit factor xa
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
AU3620799A (en) Heterocyclic derivatives which inhibit factor xa
IL117093A0 (en) Heterocyclic derivatives
IL144792A0 (en) Heterocyclic derivatives as inhibitors of factor xa
HUP0203161A2 (hu) Benzamidinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk